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Abstract
Introduction: Alterations in thyroid hormone levels occur in patients with acute neurological disease states. The aim of this study is to 
study changes in thyroid hormones in patients with brain death (BD).
Material and methods: Eleven brain-dead patients were studied prospectively. Thyroid hormones were measured on admission to the 
intensive care unit, the day before BD diagnosis (BD before), and the day after BD diagnosis (BD day). 
Results: Thyroid stimulating hormone (TSH) and free triiodothyronine (fT3) concentrations were found to be significantly low on ad-
mission, BD before, and BD day compared to age-matched healthy controls. TSH levels were shown to be increasing on BD day. Free 
thyroxine (fT4) levels were within normal limits in all cases except in one case having low fT4 levels with normal TSH levels. No statisti-
cally significant changes were encountered between admission thyroid hormone levels and BD-before and BD-day thyroid hormone 
levels. Six patients were on steroid therapy when BD-before blood samples were drawn, and no difference in thyroid hormone levels 
was encountered between steroid users and non-users. Correlation analysis showed a positive correlation between GCS and TSH, but 
a negative association between fT3 and APACHE II.
Conclusion: We have shown that patients with BD have altered thyroid hormones days before BD diagnosis, and these alterations con-
tinue until the diagnosis of BD. The changes in thyroid hormones are compatible with non-thyroidal illness syndrome. (Endokrynol Pol 
2018; 69 (5): 545–549)
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Streszczenie
Wstęp: Zmiany stężenia hormonów tarczycy występują u chorych z ostrymi chorobami neurologicznymi. Badanie przeprowadzono 
w celu oceny zmian stężeń hormonów tarczycy u chorych ze stwierdzoną śmiercią mózgu (brain death, BD).
Materiał i metody: Prospektywnym badaniem objęto 11 osób z rozpoznaniem BD. Stężenie hormonów tarczycy mierzono przy przyjęciu 
na oddział intensywnej opieki medycznej (OIOM), dzień przed rozpoznaniem BD (przed BD) i po stwierdzeniu BD (dzień BD). 
Wyniki: Stężenia tyreotropiny (thyroid stimulating hormone, TSH) oraz wolej trójjodotyroniny (free triiodothyronine, fT3) były istotnie niższe 
przy przyjęciu na OIOM, przed BD i w dniu BD niż u dobranych pod względem płci i wieku osób z grupy kontrolnej. Stwierdzono, że 
stężenie TSH wzrasta w dniu BD. Stężenia wolnej tyroksyny (fT4) mieściły się w granicach wartości prawidłowych z wyjątkiem jednego 
chorego, u którego stwierdzono niskie stężenie fT4 i prawidłowe stężenie TSH. Nie zaobserwowano statystycznie istotnych różnic między 
stężeniami hormonów tarczycy przy przyjęciu na OIOM a stężeniami mierzonymi przed BD i w dniu BD. Sześciu chorych było w trakcie 
terapii steroidowej w czasie pobierania próbek „przed BD”; nie stwierdzono różnic w stężeniach hormonów tarczycy między osobami 
leczonymi steroidami a tymi, którym nie podawano leków z tej grupy. Analiza korelacji wykazała dodatnią korelację między oceną 
w skali GCS a stężeniem TSH oraz ujemną korelację między stężeniem fT3 a oceną w skali APACHE II.
Wnioski: Wykazano, że zmiany stężeń hormonów tarczycy u chorych z BD występują w dniach poprzedzających rozpoznanie śmierci 
mózgu i utrzymują się do rozpoznania BD. Zmiany stężeń hormonów tarczycy u tych pacjentów są porównywalne ze zmianami 
obserwowanymi w non-thyroidal illness syndrome. (Endokrynol Pol 2018; 69 (5): 545–549)
Słowa kluczowe: śmierć mózgu, stan krytyczny, zespół pozatarczycowy, zaburzenia neuroendokrynologiczne
Introduction
Neuroendocrine changes occur in critically ill patients, 
with decreases in thyroid stimulating hormone (TSH), 
luteinising hormone (LH), follicle stimulating hormone 
(FSH), and growth hormone (GH) and in their end 
products of triiodothyronine (T3), testosterone, and 
insulin-like growth factor [1–3]. These alterations are 
thought to be related to the inhibitory mechanism of 
cytokines on the hypothalamic and pituitary hormone 
synthesis [4]. The hypothalamic-pituitary hormones are 
also shown to be decreased in patients with brain death 
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GCS 3 when the BD-before blood samples were drawn. 
The time interval between two blood samples was 
18–24 hours. After centrifugation, serums were stored 
at –80°C and all samples were studied in the same run. 
Since thyroid hormones were routinely measured 
among all patients admitted to our ICU in the first 
six hours, we had admission thyroid hormones of the 
patients. The following parameters were also included 
in the study: vasopressor and corticosteroid use, lac-
tate level, liver and kidney function tests, admission 
GCS, and APACHE II score. An age-matched healthy 
control group (n: 11) was used to compare hormone 
levels (patients, 57 [47–65] vs. control, 66 [50–69] years, 
p = 0.452). The study protocol was approved by the 
Ethics Review Board of Düzce University.
Standard treatments included mechanic ventilation, 
fluid resuscitation, therapeutic heating in hypothermic 
patients, desmopressin therapy if diabetes insipidus 
developed, vasopressor treatment if hypotensive after 
volume expansion, in order to keep mean arterial blood 
pressure above 65 mmHg, and insulin infusion if two 
blood glucose measures were > 180 gr/dl. Serum elec-
trolytes were normalised with appropriate amounts of 
electrolytes and free water. Diabetes insipidus was di-
agnosed by the criteria of urine output > 3 ml/kg, urine 
gravity < 1.005, and serum osmolality > 300 mosmol/L 
in 10 patients. Vasopressor treatments were started for 
all patients during BD diagnosis, norepinephrine for 10 
patients with 0.45 (0.3–1) mcg/kg/minute, and dopamine 
for one patient with 5 mcg/kg/minute. Six patients were 
treated with dexamethasone as first-line therapy after 
ICU admission, and two patients had methylpredniso-
lone therapy during the BD diagnosis period. 
Six patients were treated with dexamethasone as first-
line therapy after ICU admission. Two more patients had 
300 mg hydrocortisone equivalent methylprednisolone 
because of hypotension during the BD diagnosis period. 
The serum concentration of TSH, free triiodothy-
ronine (fT3), and free thyroxine (fT4) were measured 
by the chemiluminescence method (Advia Centaur, 
Siemens, New York, America) Normal limits: TSH: 0.35– 
–5.5 μIU/mL; fT3: 2.3–4.20 pg/mL; fT4: 0.88–1.76 ng/dL. 
All values were expressed as the median with 
interquartile ranges. Study and control groups were 
compared using the Mann-Whitney U test. The Wil-
coxon test was used to compare consecutive hormone 
values with each other. The Spearman test was used to 
show the correlation between variables. P < 0.05 was 
accepted as significant.
Results
BD diagnosis was done 2.9 (1.5–4.1) and 2.7 (1.5–3.7) 
days after hospital and ICU admissions. APACHE II 
(BD) [5–7]. These patients lose their brain function due 
to total depletion of intracerebral blood flow. Therefore, 
hormones of these glands and their end products are 
supposed to be decreased further in BD patients. TSH, 
fT3, LH, FSH, cortisol, and testosterone were demon-
strated to be low in BD patients [5–8]. On the other 
hand, prolactin and thyroxine (T4) were mainly found 
within the normal limits [5, 7, 9]. The prolactin levels 
remain normal probably due to the loss of the inhibitory 
control of hypothalamic dopamine, except in patients 
who have dopamine infusion [5, 9]. T4 remains normal 
probably due to the long half-life compared to T3 and 
TSH, which are 6–7 days, 24-30 hours, and 35 minutes, 
respectively [6]. Reverse T3 (rT3) levels were found 
to be elevated and in no case were both TSH and T4 
demonstrated to be subnormal, compatible with the 
euthyroid-sick syndrome [5, 6, 10]. The aim of this 
study was to determine changes in thyroid hormones 
in patients with BD on sequential measures from the 
moment of ICU admission until the diagnosis of BD. 
Material and methods
All consecutive BD patients diagnosed in a medical in-
tensive care unit (ICU) of a university hospital between 
May 2015 and April 2017 were included into the study. 
The study group comprised 11 patients (women/men: 
6/5), ranging in age from 24 to 78 years. BD decision was 
given in eight patients by the absence of both cerebral 
and brain stem function and positive apnoea testing, and 
in three patients by computed tomography angiogra-
phy as a confirmatory test to neurological examination 
because of the inability to conduct the apnoea testing in 
two patients and not waiting for the drug half-life in one 
patient. The legal observation time was 12 hours after the 
first neurological examination. The second neurological 
examination did not differ in all cases. All patients were 
admitted to the ICU from the emergency service, except 
for one patient from the ward after cardiopulmonary 
resuscitation. The ICU admission diagnoses were ischae-
mic cerebrovascular stroke (n: 2), intracranial bleeding 
(n: 6), hypoxic encephalopathy (n: 2), and pneumonia (n: 
1). The patient with pneumonia had left middle cerebral 
arter stroke while in the ICU on his third day. Admis-
sion Glasgow coma scores (GCS) were ≤ 5 except in one 
patient with GCS 7. Exclusion criteria were pre-existing 
endocrine diseases except diabetes mellitus. 
First blood samples (referred to as “BD before”) 
were drawn when the clinician encountered the clinical 
signs of BD such as the absence of spontaneous breath, 
polyuria, brain-stem areflexia, and drop of GCS to 3. 
Second blood samples (reffered to as "BD day") were 
taken just after the legal documentation of BD, signed 
by a neurologist and an intensivist. All patients had 
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and GCS were calculated as 26 (24–28) and 4 (3–4). All 
patients had normal kidney and liver function tests 
when they were admitted to the ICU.
When thyroid hormones of the patients were com-
pared to thyroid hormones of the control group, the 
patients had significantly lower TSH and fT3 levels 
on admission (pTSH = 0.002, pfT3 = 0.004), BD before 
(pTSH = 0.007, pfT3 < 0.001), and BD day (pTSH = 0.024, 
pfT3 < 0.001) than the control group (Table I). Then, 
admission thyroid hormones were compared to both 
the BD-before and BD-day thyroid hormones, and 
no significant differences were found. After the hor-
mones were analysed separately, it was disclosed that 
fT3 levels were subnormal in 36.3%, 54.5%, and 60% 
of the patients on admission, BD before, and BD day, 
respectively. TSH levels were below the normal limits 
in 45.5%, 45.5%, and 30% of the patients on admis-
sion, BD before, and BD day, respectively. TSH values 
were found to be increasing in six patients on BD day 
compared to BD-before values. One patient had a low 
FT4 level both on BD before and BD day with normal 
TSH levels. Sequential changes in thyroid hormones 
are shown in Figure 1. 
None of the patients was on steroid therapy when 
admission blood samples were taken. Six patients were 
on steroid treatment while BD-before blood samples 
were drawn, and no significant difference was encoun-
tered in thyroid hormone levels measured on BD before 
between steroid users and nonusers (pTSH: 0.935, pfT3: 
0.143, pfT4: 0.570). Because eight patients were on steroid 
therapy on BD day, a comparison could not be made 
between steroid users and non-users due to the limited 
number of nonusers. Lactate levels were 3.1 (1.2–4.2), 
2.0 (1.4–2.9), and 2.2 (1.0–2.8) mg/dL on admission, BD 
before, and BD day, respectively, and no statistical dif-
ference was encountered between lactate levels.
Correlation analysis showed a positive associa-
tion between TSHadmission and GCS (r: 0.743, p = 0.014) 
and a weak negative association between fT3admission 
and APACHE II (r: –0.617, p = 0.077). In addition, 
Table I. Thyroid hormone levels on admission, BD before, and BD day and their comparisons with the control group
Tabela I. Stężenia hormonów tarczycy przy przyjęciu na OIOM, przed stwierdzeniem śmierci mózgu i w dniu zdiagnozowania 
śmierci mózgu w porównaniu z wartościami zmierzonymi w grupie kontrolnej
Parameters Control Admission† BD Before BD Day¶
TSH, μIU/mL 1.56 (0.75–2.63) 0.39 (0.24–0.79)a 0.40 (0.04–1.52)a, b 0.61 (0.19–1.12)b, c
fT3, pg/mL 3.12 (2.92–3.85) 2.45 (1.51–2.65)a 1.81 (1.21–2.73)b, d 1.79 (1.38–2.79)b, d
fT4, ng/dL 1.19 (1.14–1.35) 1.12 (0.98–1.47)e 1.20 (1.01–1.80)b, e 1.18 (1.00–1.56)b, e
BD — brain death; †blood samples were drawn in the first six hours of ICU admission; BD Before — blood samples were drawn when the clinical signs of BD were first 
noticed; ¶BD Day — blood samples were drawn after the documentation of BD
ap < 0.01 vs. control; bp = not significant vs. admission; cp < 0.05 vs. control; dp < 0.001 vs. control; ep = not significant vs. control
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Figure 1. Serum TSH, fT3, and fT4 concentrations in BD patients 
from admission until BD diagnosis. Lines connect hormone 
determinations of the same subject. Thyroid hormones were not 
studied in one patient on BD day
Ryciny 1. Stężenia TSH, fT3 i fT4 w surowicy chorych 
z rozpoznaniem śmierci mózgu w okresie od przyjęcia na oddział 
OIOM do postawienia diagnozy śmierci mózgu. Linie łączą pomiary 
stężeń hormonów u tych samych chorych. U jednego chorego ze 
stwierdzoną śmiercią mózgu nie zbadano stężeń hormonów tarczycy
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negative correlations were found between fT3BDbefore 
and APCAHE II (r: –0.706, p = 0.015), between fT4BDday 
and GCS (r: –0.708, p = 0.033) and between TSHBDday 
and fT4admission (r: –0.720, p = 0.029). There was not 
any relationship between lactate levels and thyroid 
hormone levels. 
Discussion
In the present study, patients with severe cerebrovas-
cular accidents had low TSH and fT3 levels on admis-
sion to the ICU. The decrease in fT3 was continued 
as the neurological condition of the patients deterio-
rated. On the other hand, TSH levels were seen to be 
increased in six patients after brain-dead diagnosis. 
FT3 levels were disclosed to be negatively correlated 
with APACHE II, but TSH levels were positively cor-
related with GCS. 
Severe head injuries are known to be associated 
with low thyroid hormones, especially TSH and fT3. 
Olivecroen et al. showed that patients with severe 
brain injury who died at three months had lower acute 
TSH levels on day 1 and day 4 than did those who 
survived [3]. Additionally, TSH levels were noticed to 
be increasing in survivors and in patients with good 
neurologic outcomes from day 1 to day 4, whereas they 
remained low in non-survivors. TSH was discovered 
to be negatively correlated with neurological disease 
severity indexes, as shown in our study. Similar results 
were also shown for fT3, where fT3 level was shown 
to be significantly low at day 4 in patients who died 
within three months. A study done by Cernak et al. 
reported that patients with GCS 4–6 due to traumatic 
brain injury had a significant decline in TSH and 
T3 concentrations compared to patients with GCS 
13–15 in a seven-day observation period [11]. Brain 
injured patients with complicated clinical course were 
demon strated to have low mean seven-day TSH and 
T3 concentrations than patients with uncomplicated 
clinical course in another study [12]. The decreases in 
thyroid hormones were shown in cranial haemorrhage, 
traumatic brain injury, and ischaemic events [4, 11–13]. 
The critical point here is the severity of brain injury; 
the worse the neurological disease severity indexes 
are, the greater the decrease in TSH and T3 [3, 11, 12]. 
Low thyroid hormone concentrations at the early 
phase of neurological diseases were demonstrated to 
be correlated with unfavourable six-month and one-
year neurological outcomes [12, 13]. Similar to those 
studies, our patients with severe brain injuries had 
low median TSH and fT3 levels on admission and also 
on follow-up. The decrease in TSH is probably due to 
cytokine-related hypothalamic TRH suppression, as 
documented in the studies [4, 14]. 
The decline in T3 occurs in acute disease states, in-
cluding those patients admitted to the ICU due to any 
critical illness, or those patients having major surgery [1]. 
The drop in T3 level is thought to be an adaptive re-
sponse to reduce energy expenditure, as happens in 
fasting healthy subjects [1]. Cytokines released during 
acute disease states are considered to be responsible for 
the decreased conversion of T4 to T3 in the peripheral 
tissues by altering the activity and expression of deio-
dinase enzymes of D1, D3, and D3 [1, 15]. Additionally, 
thyroid hormone synthesis is down regulated by the 
cytokines, leading to deceased secretion of T4 and T3 
from the thyroid gland [15]. Considering our patient, 
they had severe acute diseases requiring ICU admis-
sion. Their condition was getting worse and ended 
up with BD in a short time. Therefore, the percentage 
of patients with low fT3 increased as time passed. In 
contrast to T3, T4 generally remains normal or some-
times decreases in acute disease states. Low T4 level is 
mostly encountered in the chronic phase of acute illness 
(from seven days onwards) [1]. This could be due to its 
long half-life, which is 6–7 days. The median time from 
hospital admission to BD was three days in our study, 
which was not enough time to meet declined T4 levels. 
There are several studies showing drops in TSH and 
T3 concentrations, and to some extent in T4 concentra-
tion in patients with BD [5–7, 9, 10]. The main point of 
these studies is to have the serum measurement of the 
hormones after the diagnosis of BD and no early hor-
monal measurements exist to compare them with each 
other, except in two studies. A study done by Masson 
et al. showed low fT3, fT4, and TSH levels in 80%, 65%, 
and 50% of BD patients on sequential measurements, 
respectively [16]. Luckily, thyroid hormone levels 
were measured before BD in seven out of 20 patients. 
They did not show any difference between hormonal 
levels measured before and after BD, similarly to our 
results. Pownear et al. also did not show any statistically 
significant changes between thyroid hormone levels 
measured before and after BD diagnosis, and showed 
that 88% of the subjects had low fT3 levels before BD 
diagnosis [6]. Another hallmark of the euthyroid-sick 
syndrome is the increased reverse T3 (rT3) [1, 15]. rT3 
was measured as high in BD subjects in a number of 
studies [5, 6, 17]. Increments in TSH levels on sequen-
tial measurements after BD were also demonstrated in 
studies, as we have shown [7, 9, 10]. This increase could 
be due to complete necrosis of the pituitary gland, thus 
releasing the preformed TSH into the circulation [7]. 
There are some limitations of this study. First, it included 
a limited number of patients, although the statistical 
results were meaningful. Second, we did not measure 
rT3, which would strengthen our hypothesis of the 
euthyroid-sick syndrome. 
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Conclusions
We have shown that patients with severe cerebrovascu-
lar accident had decreased TSH levels both on admis-
sion to the ICU and after BD diagnosis. The median 
level of fT3 was also measured to be subnormal from 
ICU admission until the BD diagnosis. The decrement in 
fT3 level was negatively correlated with APACHE II. FT4 
levels were similar to their healthy controls. The results 
were compatible with the euthyroid-sick syndrome, 
which are seen in many acute disease states in the ICU. 
Therefore, thyroid hormonal changes encountered in 
BD patients can be considered as part of non-thyroidal 
illness syndrome.
Acknowledgement
Part of this study was presented in the 14th Congress 
of the International Society for Organ Donation and 
Procurement, September 6–9, Geneva, 2017. 
Authorship
T. Akbaş designed the study, followed the patients, 
gathered the raw data of the study, and contributed 
to writing the paper. İE Şahin did the laboratory work 
and contributed to writing the assay part of the manu-
script. A. Öztürk designed and followed the study and 
contributed to writing the manuscript. All authors read, 
edited, and ultimately approved the final manuscript. 
Conflict of interest
The authors declared that there are no conflicts of 
interest. 
Funding
The authors declared that this study received no fi-
nancial support. The authors have charged the study.
References
1. Boonen E, Berghe GV. Endocrine Responses to Critical Illness: Novel 
Insights and Therapeutic Implications. J Clin Endocrinol Metab. 2014; 
99(5): 1569–1582, doi: 10.1210/jc.2013-4115, indexed in Pubmed: 24517153.
2. Fourrier F, Jallot A, Leclerc L, et al. Sex steroid hormones in circula-
tory shock, sepsis syndrome, and septic shock. Circ Shock. 1994; 43(4): 
171–178, indexed in Pubmed: 7895322.
3. Olivecrona Z, Dahlqvist P, Koskinen LOD. Acute neuro-endocrine profile 
and prediction of outcome after severe brain injury. Scand J Trauma 
Resusc Emerg Med. 2013; 21: 33, doi: 10.1186/1757-7241-21-33, indexed 
in Pubmed: 23601250.
4. Boelen A, Kwakkel J, Thijssen-Timmer DC, et al. Simultaneous changes 
in central and peripheral components of the hypothalamus-pituitary-
thyroid axis in lipopolysaccharide-induced acute illness in mice. 
J Endocrinol. 2004; 182(2): 315–323, indexed in Pubmed: 15283692.
5. Howlett TA, Keogh AM, Perry L, et al. Anterior and posterior pituitary 
function in brain-stem-dead donors. A possible role for hormonal 
replacement therapy. Transplantation. 1989; 47(5): 828–834, indexed in 
Pubmed: 2718243.
6. Powner DJ, Hendrich A, Lagler RG, et al. Hormonal changes in brain 
dead patients. Crit Care Med. 1990; 18(7): 702–708, indexed in Pubmed: 
2194745.
7. Gramm HJ, Meinhold H, Bickel U, et al. Acute endocrine failure after 
brain death? Transplantation. 1992; 54(5): 851–857, indexed in Pubmed: 
1332223.
8. Dimopoulou I, Tsagarakis S, Anthi A, et al. High prevalence of decreased 
cortisol reserve in brain-dead potential organ donors. Crit Care Med. 
2003; 31(4): 1113–1117, doi: 10.1097/01.CCM.0000059644.54819.67, in-
dexed in Pubmed: 12682481.
9. Harms J, Isemer FE, Kolenda H. Hormonal alteration and pituitary 
function during course of brain-stem death in potential organ donors. 
Transplant Proc. 1991; 23(5): 2614–2616, indexed in Pubmed: 1926503.
10. Keogh AM, Howlett TA, Perry L, et al. Pituitary function in brain-stem 
dead organ donors: a prospective survey. Transplant Proc. 1988; 20(5): 
729–730, indexed in Pubmed: 3188180.
11. Cernak I, Savic VJ, Lazarov A, et al. Neuroendocrine responses follow-
ing graded traumatic brain injury in male adults. Brain Inj. 1999; 13(12): 
1005–1015, indexed in Pubmed: 10628505.
12. Zetterling M, Engström B, Arnardottir S, et al. Somatotropic and thy-
roid hormones in the acute phase of subarachnoid haemorrhage. Acta 
Neurochir. 2013; 155(11): 2053–2062, doi: 10.1007/s00701-013-1670-8, 
indexed in Pubmed: 23494135.
13. Marina D, Klose M, Nordenbo A, et al. Early endocrine alterations reflect 
prolonged stress and relate to 1-year functional outcome in patients with 
severe brain injury. Eur J Endocrinol. 2015; 172(6): 813–822, doi: 10.1530/
EJE-14-1152, indexed in Pubmed: 25825347.
14. Fliers E, Guldenaar SE, Wiersinga WM, et al. Decreased hypothalamic 
thyrotropin-releasing hormone gene expression in patients with non-
thyroidal illness. J Clin Endocrinol Metab. 1997; 82(12): 4032–4036, doi: 
10.1210/jcem.82.12.4404, indexed in Pubmed: 9398708.
15. de Vries EM, Fliers E, Boelen A. The molecular basis of the non-thyroidal 
illness syndrome. J Endocrinol. 2015; 225(3): R67–R81, doi: 10.1530/JOE-
15-0133, indexed in Pubmed: 25972358.
16. Masson F, Thicoïpe M, Latapie MJ, et al. Thyroid function in brain-dead 
donors. Transpl Int. 1990; 3(4): 226–233, indexed in Pubmed: 2076172.
